PDI - Resultado de Búsqueda

Christian Lorenzo Caglevic Medina

Director Científico

Fundación Arturo Lopez Perez

Santiago, Chile

Participación en clinical trials desde 2008 en cáncer

Oncology, UNIVERSIDAD DE SANTIAGO DE CHILE. Chile, 2008

Director Cientifico Departamento de Investigacion del cancer Full Time

Santiago, Chile

2020 - At present

Academic Part Time

Universidad de Chile

Santiago, Chile

2002 - 2009
Medical Oncologist Part Time

Hospital Barros Luco Trudeau

Santiago, Chile

2004 - 2012
Medical Oncologist Part Time

Hospital Clínico Universidad de Chile

Santiago, Chile

2007 - 2009
Medical Oncologist Part Time

Fundación Arturo Lopez Perez de Santiago (2009-2018)

Santiago, Chile

2009 - 2018
Medical Oncologist Full Time

Clinica Alemana Santiago

Santiago, Chile

2018 - 2020
Head of lnvestigational Cancer Drugs Unit (UIDO- FALP) Part Time

Fundación Arturo Lopez Perez

Santiago, Chile

2016 - 2018
Head of Cancer Research Department Full Time

Fundación Arturo Lopez Perez

Santiago, Chile

2020 - At present

Experiencia en Investigación clínica, Director Científico de Departamento de Investigación del Cáncer
A cargo de Unidad de Estudios Clínicos, Unidad de Investigación y Docencia, Unidad de Medicina Traslacional
Fundacion Arturo Lopez Perez


Pharmacokinetics and bioavailability of pembrolizumab with berahyaluronidase alfa for subcutaneous administration in participants with advanced or metastatic solid tumors: The phase 1 study 3475A-C18 Cohen, GL; Coetzee, C; Walton, CA; Torras, OR; Cho, BC; Mcadam, G; Rojas C.I.; Rodríguez, LM; Papai, Z; Chan S.W.; et al. Article ISI SCOPUS European Journal of Cancer (2025)
Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial Shitara K.; Di Bartolomeo M.; Mandala M.; Ryu M.H.; Caglevic C.; Olesinski T.; Chung H.C.; Muro K.; Goekkurt E.; McDermott, RS; et al. Article ISI SCOPUS Journal for ImmunoTherapy of Cancer (2023)
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score=1% in the KEYNOTE-042 Study De Castro G.; Kudaba I.; Wu Y.L.; Lopes, G; Kowalski, DM; Turna, HZ; Caglevic C.; Zhang L.; Karaszewska B.; Laktionov, KK; et al. Article ISI SCOPUS Journal of Clinical Oncology (2023)
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial Christian Caglevic Article Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. (2022)
Takotsubo cardiomyopathy Afatinib-related in a non-small cell lung cancer patient: Case report Ramos G.E.; Caglevic C.; Bulnes J.F.; Panay S.E.; Zapata M.I.; Daniele A.J.; Rodriguez M.E. Article ISI SCOPUS Frontiers in Cardiovascular Medicine (2022)
The current situation for gastric cancer in Chile Christian Caglevic Article ECANCERMEDICALSCIENCE (2022)
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma Christian Caglevic Article The New England journal of medicine. (2021)
Clinical characterization and treatment of head and neck mucosal melanoma: a Chilean experience Christian Caglevic Article ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY (2021)
Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial Christian Caglevic Article PLOS MEDICINE (2021)
Incidence of lung cancer and air pollution in boroughs of Chile: an ecological study Christian Caglevic Article ECANCERMEDICALSCIENCE (2021)
Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma Shitara K.; ÃƒÂ–zgÃƒÂ¼roÃ„ÂŸlu M.; Bang Y.J.; Di Bartolomeo M.; MandalÃƒÂ M.; Ryu M.H.; Caglevic C.; Chung H.C.; Muro K.; Van Cutsem E.; et al. Article SCOPUS Annals of Oncology (2021)
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial Christian Caglevic Article LANCET ONCOLOGY (2021)
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer Christian Caglevic Article The New England journal of medicine. (2021)
Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: impact on pathological complete response and safety Christian Caglevic Article ECANCERMEDICALSCIENCE (2021)
[Cancer immunotherapy: an update] Christian Caglevic Article Revista me?dica de Chile (2020)
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial Christian Caglevic Article JAMA ONCOLOGY (2020)
Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8 + T Cells Christian Caglevic Article CANCERS (2020)
Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies Christian Caglevic Article TRANSLATIONAL LUNG CANCER RESEARCH (2020)
Potential use of n-3 PUFAs to prevent oxidative stress-derived ototoxicity caused by platinum-based chemotherapy Christian Caglevic Article FREE RADICAL BIOLOGY AND MEDICINE (2020)
Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID-19 pandemic: the THOCOoP cooperative group Christian Caglevic Article Critical reviews in oncology/hematology. (2020)
Barriers in Latin America for the management of locally advanced breast cancer Christian Caglevic Article ECANCERMEDICALSCIENCE (2019)
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study Christian Caglevic Article The Lancet. Oncology (2019)
Mesenchymal stem cell therapy for doxorubicin cardiomyopathy: hopes and fears Christian Caglevic Article ECANCERMEDICALSCIENCE (2019)
Oncogenic role of arsenic exposure in lung cancer: A forgotten risk factor Christian Caglevic Article Critical reviews in oncology/hematology. (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Christian Caglevic Article Lancet (London, England) (2019)
Triple-negative breast cancer: the reality in Chile and in Latin America Christian Caglevic Article ECANCERMEDICALSCIENCE (2019)
Immunotherapy in Lung Cancer: A New Age in Cancer Treatment Christian Caglevic Article ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY (2018)
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial Christian Caglevic Article European journal of cancer : official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR). (2018)
The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments Christian Caglevic Article FREE RADICAL BIOLOGY AND MEDICINE (2018)
Vaccine and immune cell therapy in non-small cell lung cancer Christian Caglevic Article Journal of thoracic disease. (2018)
Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found… Christian Caglevic Article ESMO open. (2017)
Immunotherapy in NSCLC: A Promising and Revolutionary Weapon Christian Caglevic Article ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY (2017)
Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib Christian Caglevic Article Critical reviews in oncology/hematology. (2017)
[Recommendations for the management of pancreatic cancer type adenocarcinoma: A consensus statement reached during the 2015 Latin American Symposium on Gastroenterological Oncology] Christian Caglevic Article REVISTA MEDICA DE CHILE (2016)
BRAF mutations in non-small cell lung cancer: has finally Janus opened the door? Christian Caglevic Article Critical reviews in oncology/hematology. (2016)
Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015 Christian Caglevic Article ESMO Open (2016)
Hepatocellular carcinoma in identical twins in Chile: case report Christian Caglevic Article ECANCERMEDICALSCIENCE (2016)
The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer Christian Caglevic Article EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
Nintedanib in non-small cell lung cancer: from preclinical to approval Christian Caglevic Article THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2015)
A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer Christian Caglevic Article BREAST CANCER RESEARCH AND TREATMENT (2014)
Final overall survival analysis of a phase II trial evaluating vinorelbine and lapatinib in women with ErbB2 overexpressing metastatic breast cancer Christian Caglevic Article The Breast : official journal of the European Society of Mastology. (2014)
Report from the First Latin American Urological Oncology Symposium (SLAURO) 19-21 June 2014, Viña del Mar, Chile Christian Caglevic Article ECANCERMEDICALSCIENCE (2014)
Latin american symposium on oncological gastroenterology Christian Caglevic Article ECANCERMEDICALSCIENCE (2013)
[Relapse of Hodgkin disease after 17 years of complete remission. A case report] Christian Caglevic Article REVISTA MEDICA DE CHILE (2003)
Relapse of Hodgkin disease after 17 years of complete remission. Report of one case Osorio G.; Caglevic C. Article ISI REVISTA MEDICA DE CHILE (2003)


Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair-deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study Rojas C.; Eskens F.; Ghiringhelli F.; Özgüroglu, M; Caglevic C.; Gumus M.; Tosi D.; Grenier J.; GonzÃ¡lez Ã.F.; Arenas A.; et al. Abstract ISI JOURNAL OF CLINICAL ONCOLOGY (2024)
Association between gene expression signatures and outcomes of pembrolizumab (pembro) and paclitaxel (pac) in advanced gastric cancer (GC): Exploratory analysis from KEYNOTE-061 Shitara K.; Di Bartolomeo M.; Mandala M.; Ryu M.H.; Caglevic C.; Olesinski T.; Chung H.C.; Muro K.; Goekkurt E.; McDermott, RS; et al. Abstract ISI (2022)
Phase 1/ 2 study of quavonlimab (Qmab) plus pembrolizumab (pembro) in patients (pts) with advanced melanoma that progressed on a PD-1/PD-L1 inhibitor Deva, S; Mackiewicz J.; Dalle S.; Gogas, H; Lugowska, I; Berrocal A.; Menzies A.M.; Maio, M; Nagrial, A; Eizmendi, KM; et al. Abstract ISI (2022)
A phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for HER2 overexpressing metastatic breast cancer (MBC). Papadimitriou, CA; Sarosiek, T; Pikiel, J; Karaszewska B.; Salat C.; Caglevic C.; Potemski, P; Brain, E; Briggs, KJ; DeSilvio, M; et al. Abstract ISI JOURNAL OF CLINICAL ONCOLOGY (2013)


Chemotherapy beyond the second line of treatment in non-small cell lung cancer: New drug development Rolfo C.; Caglevic C.; Mahave M.; Bustamante E.; Castanon, E; Bazo I.G.; Márquez-Medina D. BookWhole SCOPUS Fighting Lung Cancer with Conventional Therapies (2015)


Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repairâdeficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study. Rojas C.; Eskens F.; Ghiringhelli F.; ÃƒÂ–zgÃƒÂ¼roÃ„ÂŸlu M.; Caglevic C.; Gumus M.; Tosi D.; Grenier J.; Falcon Gonzalez A.; Arenas A.; et al. Review SCOPUS Journal of Clinical Oncology (2024)
Considerations and analysis of the implementation of oncogeriatrics in Chile and its importance: Review of current literature Honorato M.; Calderón, O; Rojas V.; Fasce, G; Bartolotti, C; Caglevic C. Review ISI SCOPUS Frontiers in Aging (2023)

Christian Caglevic

Director Científico

Departamento de Investigación del Cáncer

Fundación Arturo Lopez Perez

Santiago, Chile

Christian Lorenzo Caglevic Medina

Líneas de Investigación

Educación

Oncology, UNIVERSIDAD DE SANTIAGO DE CHILE. Chile, 2008

Experiencia Académica

Director Cientifico Departamento de Investigacion del cancer Full Time

Experiencia Profesional

Academic Part Time

Medical Oncologist Part Time

Medical Oncologist Part Time

Medical Oncologist Part Time

Medical Oncologist Full Time

Head of lnvestigational Cancer Drugs Unit (UIDO- FALP) Part Time

Head of Cancer Research Department Full Time

Formación de Capital Humano

Article (45)

Abstract (4)

BookWhole (1)

Review (2)